BioCryst Pharmaceuticals (Nasdaq: BCRX) will receive $1.1 million in federal grants to support development of five potential drugs it has under development.

The RTP-based firm is one of several in the Triangle to be chosen for funding by the Department of Health and Human Services through the Patient Protection and Affordable Care Act.

Some $1 billion in federal funding was available, with the money intended to help underwrite the costs of drug development.

The legislation targeted firms with fewer than 250 employees. Grants were available for up to 50 percent for expenses directly related to drugs selected for the program.

BioCryst’s grants were for its Peramivir, BCX4208, Forodesine and two pre-clinical programs.

“We are pleased to receive these grants and to have our clinical and pre-clinical programs recognized as potential treatment options to address unmet medical needs,” said Jon Stonehouse, BioCryst’s chief executive officer.

“BioCryst remains committed to advancing novel therapeutics for patients with serious diseases and these grants will help to further each of these programs,” he added.

BioCryst is focused on drugs that block enzymes in infectious diseases, inflammatory diseases and cancer.

Peramivir targets influenza. BCX4208 is intended as a treatment for gout. Forodesine is intended to fight hematological malignancies.

Get the latest news alerts: at Twitter.